[Form 4] Idexx Laboratories Inc Insider Trading Activity
Jonathan Jay Mazelsky, who is reported as a Director and the President and CEO of IDEXX Laboratories, reported an insider transaction involving common stock and a related option. The Form 4 shows an acquisition of 183 shares of common stock on 08/08/2025 at a price of $598.488 per share, with reported beneficial ownership following the transaction of 83,494.3016 shares (direct).
The filing also discloses a Premium Incentive Stock Option tied to 183 underlying shares with an exercise/conversion price of $598.488. The explanatory note states the option was granted at a 110% premium to the closing price on February 12, 2021 and became exercisable in one installment on February 14, 2025. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Mazelsky.
Jonathan Jay Mazelsky, indicato come Director e President and CEO di IDEXX Laboratories, ha comunicato un'operazione insider riguardante azioni ordinarie e un'opzione correlata. Il Form 4 riporta l'acquisto di 183 azioni ordinarie in data 08/08/2025 al prezzo di $598.488 per azione, con una partecipazione beneficiaria risultante dopo l'operazione pari a 83,494.3016 azioni (dirette).
Il documento indica inoltre una Premium Incentive Stock Option su 183 azioni sottostanti con prezzo di esercizio/conversione di $598.488. La nota esplicativa precisa che l'opzione 猫 stata concessa con un premio del 110% rispetto al prezzo di chiusura del 12 febbraio 2021 e che 猫 divenuta esercitabile in un'unica tranche il 14 febbraio 2025. Il Form 4 猫 firmato da un mandatario munito di procura per conto del sig. Mazelsky.
Jonathan Jay Mazelsky, mencionado como Director y President and CEO de IDEXX Laboratories, inform贸 una operaci贸n interna relacionada con acciones ordinarias y una opci贸n vinculada. El Form 4 muestra la adquisici贸n de 183 acciones ordinarias el 08/08/2025 a un precio de $598.488 por acci贸n, con una participaci贸n beneficiaria posterior a la operaci贸n de 83,494.3016 acciones (directas).
La presentaci贸n tambi茅n revela una Premium Incentive Stock Option sobre 183 acciones subyacentes con precio de ejercicio/conversi贸n de $598.488. La nota explicativa indica que la opci贸n fue otorgada con una prima del 110% respecto al precio de cierre del 12 de febrero de 2021 y que se volvi贸 ejercitable en un 煤nico tramo el 14 de febrero de 2025. El Form 4 est谩 firmado por un apoderado en representaci贸n del Sr. Mazelsky.
Jonathan Jay Mazelsky電� IDEXX Laboratories鞚� Director鞚挫瀽 President and CEO搿� 氤搓碃霅橃棃鞙茧┌, 氤错喌欤� 氚� 甏�霠� 鞓奠厴鞐� 甏�頃� 雮措秬鞛� 瓯半灅毳� 鞁犼碃頄堨姷雼堧嫟. Form 4鞐愲姅 2025-08-08鞐� 氤错喌欤� 183欤茧ゼ 欤茧嫻 $598.488鞐� 旆摑頃� 瓴冹溂搿� 旮办灛霅橃柎 鞛堨溂氅�, 瓯半灅 頉� 氤搓碃霅� 鞁れ鞝� 氤挫湢電� 83,494.3016欤�(歆侅爲 氤挫湢)搿� 雮橅儉雮� 鞛堨姷雼堧嫟.
鞁犼碃靹滌棎電� 霕愴暅 旮办磮 欤检嫕 183欤检棎 雽�頃� Premium Incentive Stock Option鞚� 鞛堦碃, 頄夓偓臧�/鞝勴櫂 臧�瓴╈潃 $598.488搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 靹る獏霝�鞐愲姅 鞚� 鞓奠厴鞚� 2021雲� 2鞗� 12鞚� 膦呹皜氤措嫟 110% 頂勲Μ氙胳梽鞙茧 攵�鞐悩鞐堦碃, 2025雲� 2鞗� 14鞚� 雼澕 攵勴暊搿� 頄夓偓 臧�電ロ晿瓴� 霅橃棃雼�瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. Form 4電� 毵堨牑鞀ろ偆 鞌ゼ 雽�鞁犿暣 鞙勳瀯鞚� 氚涭潃 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Jonathan Jay Mazelsky, signal茅 comme Director et President and CEO d'IDEXX Laboratories, a d茅clar茅 une transaction d'initi茅 portant sur des actions ordinaires et une option connexe. Le Form 4 indique l'acquisition de 183 actions ordinaires le 08/08/2025 au prix de $598.488 par action, avec une propri茅t茅 b茅n茅ficiaire d茅clar茅e apr猫s la transaction de 83,494.3016 actions (directes).
Le d茅p么t divulgue 茅galement une Premium Incentive Stock Option li茅e 脿 183 actions sous-jacentes avec un prix d'exercice/de conversion de $598.488. La note explicative pr茅cise que l'option a 茅t茅 accord茅e avec une prime de 110% par rapport au cours de cl么ture du 12 f茅vrier 2021 et qu'elle est devenue exer莽able en une seule tranche le 14 f茅vrier 2025. Le Form 4 est sign茅 par un mandataire agissant au nom de M. Mazelsky.
Jonathan Jay Mazelsky, der als Director sowie President and CEO von IDEXX Laboratories angegeben ist, meldete eine Insider-Transaktion in Bezug auf Stammaktien und eine zugeh枚rige Option. Das Form 4 zeigt den Erwerb von 183 Stammaktien am 08/08/2025 zum Preis von $598.488 je Aktie, mit einem nach der Transaktion gemeldeten wirtschaftlichen Eigentum von 83,494.3016 Aktien (direkt).
Die Einreichung legt au脽erdem eine Premium Incentive Stock Option auf 183 zugrunde liegende Aktien mit einem Aus眉bungs-/Umwandlungspreis von $598.488 offen. Die erl盲uternde Bemerkung besagt, dass die Option mit einem 110%igen Aufschlag gegen眉ber dem Schlusskurs vom 12. Februar 2021 gew盲hrt wurde und am 14. Februar 2025 in einer einzigen Tranche aus眉bbar wurde. Das Form 4 ist von einem Bevollm盲chtigten im Namen von Herrn Mazelsky unterschrieben.
- None.
- None.
Insights
TL;DR: Routine insider exercise of a small number of shares by the CEO; transaction appears administrative, not a sale.
The report documents an acquisition of 183 shares at $598.488 per share via a Premium Incentive Stock Option, leaving reported direct beneficial ownership of 83,494.3016 shares. For public-market investors, the absolute size of the transaction is small relative to typical outstanding share counts for large-cap companies, and it is recorded as an acquisition rather than a disposition. The explanatory note clarifies the option grant terms (110% premium to the Feb 12, 2021 closing price) and exercisability in one installment on Feb 14, 2025. This appears to be a routine exercise of executive stock compensation rather than an indicator of change in control or liquidity event.
TL;DR: Insider exercise aligns with longstanding equity compensation; governance implications are limited absent additional transactions.
Mr. Mazelsky is listed as both Director and President and CEO, and the Form 4 documents exercise-related activity for a Premium Incentive Stock Option covering 183 shares at an exercise price of $598.488. The explanatory language discloses the original grant premium and the single-installment exercisability date, indicating standard executive award mechanics. No sales or transfers are reported here, and the form shows direct ownership post-transaction. From a governance perspective, this filing documents execution of compensation rights rather than compensation policy changes or related-party arrangements that would warrant heightened scrutiny.
Jonathan Jay Mazelsky, indicato come Director e President and CEO di IDEXX Laboratories, ha comunicato un'operazione insider riguardante azioni ordinarie e un'opzione correlata. Il Form 4 riporta l'acquisto di 183 azioni ordinarie in data 08/08/2025 al prezzo di $598.488 per azione, con una partecipazione beneficiaria risultante dopo l'operazione pari a 83,494.3016 azioni (dirette).
Il documento indica inoltre una Premium Incentive Stock Option su 183 azioni sottostanti con prezzo di esercizio/conversione di $598.488. La nota esplicativa precisa che l'opzione 猫 stata concessa con un premio del 110% rispetto al prezzo di chiusura del 12 febbraio 2021 e che 猫 divenuta esercitabile in un'unica tranche il 14 febbraio 2025. Il Form 4 猫 firmato da un mandatario munito di procura per conto del sig. Mazelsky.
Jonathan Jay Mazelsky, mencionado como Director y President and CEO de IDEXX Laboratories, inform贸 una operaci贸n interna relacionada con acciones ordinarias y una opci贸n vinculada. El Form 4 muestra la adquisici贸n de 183 acciones ordinarias el 08/08/2025 a un precio de $598.488 por acci贸n, con una participaci贸n beneficiaria posterior a la operaci贸n de 83,494.3016 acciones (directas).
La presentaci贸n tambi茅n revela una Premium Incentive Stock Option sobre 183 acciones subyacentes con precio de ejercicio/conversi贸n de $598.488. La nota explicativa indica que la opci贸n fue otorgada con una prima del 110% respecto al precio de cierre del 12 de febrero de 2021 y que se volvi贸 ejercitable en un 煤nico tramo el 14 de febrero de 2025. El Form 4 est谩 firmado por un apoderado en representaci贸n del Sr. Mazelsky.
Jonathan Jay Mazelsky電� IDEXX Laboratories鞚� Director鞚挫瀽 President and CEO搿� 氤搓碃霅橃棃鞙茧┌, 氤错喌欤� 氚� 甏�霠� 鞓奠厴鞐� 甏�頃� 雮措秬鞛� 瓯半灅毳� 鞁犼碃頄堨姷雼堧嫟. Form 4鞐愲姅 2025-08-08鞐� 氤错喌欤� 183欤茧ゼ 欤茧嫻 $598.488鞐� 旆摑頃� 瓴冹溂搿� 旮办灛霅橃柎 鞛堨溂氅�, 瓯半灅 頉� 氤搓碃霅� 鞁れ鞝� 氤挫湢電� 83,494.3016欤�(歆侅爲 氤挫湢)搿� 雮橅儉雮� 鞛堨姷雼堧嫟.
鞁犼碃靹滌棎電� 霕愴暅 旮办磮 欤检嫕 183欤检棎 雽�頃� Premium Incentive Stock Option鞚� 鞛堦碃, 頄夓偓臧�/鞝勴櫂 臧�瓴╈潃 $598.488搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 靹る獏霝�鞐愲姅 鞚� 鞓奠厴鞚� 2021雲� 2鞗� 12鞚� 膦呹皜氤措嫟 110% 頂勲Μ氙胳梽鞙茧 攵�鞐悩鞐堦碃, 2025雲� 2鞗� 14鞚� 雼澕 攵勴暊搿� 頄夓偓 臧�電ロ晿瓴� 霅橃棃雼�瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. Form 4電� 毵堨牑鞀ろ偆 鞌ゼ 雽�鞁犿暣 鞙勳瀯鞚� 氚涭潃 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Jonathan Jay Mazelsky, signal茅 comme Director et President and CEO d'IDEXX Laboratories, a d茅clar茅 une transaction d'initi茅 portant sur des actions ordinaires et une option connexe. Le Form 4 indique l'acquisition de 183 actions ordinaires le 08/08/2025 au prix de $598.488 par action, avec une propri茅t茅 b茅n茅ficiaire d茅clar茅e apr猫s la transaction de 83,494.3016 actions (directes).
Le d茅p么t divulgue 茅galement une Premium Incentive Stock Option li茅e 脿 183 actions sous-jacentes avec un prix d'exercice/de conversion de $598.488. La note explicative pr茅cise que l'option a 茅t茅 accord茅e avec une prime de 110% par rapport au cours de cl么ture du 12 f茅vrier 2021 et qu'elle est devenue exer莽able en une seule tranche le 14 f茅vrier 2025. Le Form 4 est sign茅 par un mandataire agissant au nom de M. Mazelsky.
Jonathan Jay Mazelsky, der als Director sowie President and CEO von IDEXX Laboratories angegeben ist, meldete eine Insider-Transaktion in Bezug auf Stammaktien und eine zugeh枚rige Option. Das Form 4 zeigt den Erwerb von 183 Stammaktien am 08/08/2025 zum Preis von $598.488 je Aktie, mit einem nach der Transaktion gemeldeten wirtschaftlichen Eigentum von 83,494.3016 Aktien (direkt).
Die Einreichung legt au脽erdem eine Premium Incentive Stock Option auf 183 zugrunde liegende Aktien mit einem Aus眉bungs-/Umwandlungspreis von $598.488 offen. Die erl盲uternde Bemerkung besagt, dass die Option mit einem 110%igen Aufschlag gegen眉ber dem Schlusskurs vom 12. Februar 2021 gew盲hrt wurde und am 14. Februar 2025 in einer einzigen Tranche aus眉bbar wurde. Das Form 4 ist von einem Bevollm盲chtigten im Namen von Herrn Mazelsky unterschrieben.
FAQ
Who filed the Form 4 for IDEXX (IDXX)?
What transaction is reported on the Form 4 for IDXX?
How many shares did Mr. Mazelsky beneficially own after the reported transaction?
Was a derivative security involved in the transaction?
When did the option become exercisable according to the filing?
Who signed the Form 4 on behalf of Mr. Mazelsky?
